Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
409 studies found for:    Open Studies | "Uterine Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Assisted Exercise in Obese Endometrial Cancer Patients
Conditions: Stage I Endometrial Adenocarcinoma;   Uterine Cancer;   Obesity
Interventions: Behavioral: Exercise on stationary recumbent exercise cycle;   Behavioral: Health Education;   Behavioral: Questionnaires;   Procedure: Neuroimaging;   Procedure: Genetic and Biomarkers
22 Recruiting Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Lung Cancer;   Melanoma;   Non-Hodgkin's Lymphoma;   Uterine Cancer;   CORPUS UTERI,ENDOMETRIUM;   LUNG;   OVARY
Intervention:
23 Recruiting Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen
Conditions: Breast Cancer;   Ovarian Cancer;   Cancer of the Uterus
Interventions: Drug: GDC-0032;   Drug: Tamoxifen
24 Recruiting A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Condition: Endometrial Cancer
Intervention: Drug: Carboplatin AUC and Abraxane 100mg/m2
25 Recruiting Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
Conditions: Breast Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Uterine Corpus Cancer;   Uterine Corpus Carcinosarcoma
Interventions: Drug: Metformin Hydrochloride;   Drug: Doxycycline
26 Not yet recruiting Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
Conditions: Endometrial Serous Adenocarcinoma;   Stage I Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Stage III Uterine Corpus Cancer;   Stage IV Uterine Corpus Cancer
Interventions: Other: Diagnostic Laboratory Biomarker Analysis;   Other: Immunohistochemistry Staining Method;   Other: Medical Chart Review;   Genetic: Microarray Analysis;   Other: Study of Socioeconomic and Demographic Variables;   Genetic: Western Blotting
27 Recruiting Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Conditions: Stage IA Uterine Sarcoma;   Stage IB Uterine Sarcoma;   Stage IC Uterine Sarcoma;   Stage IIA Uterine Sarcoma;   Stage IIB Uterine Sarcoma;   Stage IIIA Uterine Sarcoma;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Other: laboratory biomarker analysis
28 Recruiting Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Conditions: Endometrial Serous Adenocarcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC1 Uterine Corpus Cancer;   Stage IIIC2 Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
29 Recruiting Improving the Treatment for Women With Early Stage Cancer of the Uterus
Conditions: Complex Endometrial Hyperplasia With Atypia;   Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Drug: Levonorgestrel;   Drug: Metformin
30 Recruiting The Role of Indocyanine Green to Identify Sentinel Lymph Node in Uterine Cancer
Condition: Endometrial Neoplasm
Intervention: Procedure: Sentinel lymph node mapping
31 Recruiting Lymphedema After Primary Surgery for Endometrial Cancer
Conditions: Carcinoma of the Endometrium;   Hysterectomy;   Lymphadenectomy
Intervention: Procedure: Lymphadenectomy
32 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
33 Not yet recruiting Pembro/Carbo/Taxol in Endometrial Cancer
Conditions: Endometrial Cancer;   Endometrial Adenocarcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin
34 Recruiting Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Conditions: Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IVA Uterine Corpus Cancer
Interventions: Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation Therapy
35 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin
36 Not yet recruiting Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy
Condition: Endometrial Polyps
Interventions: Procedure: Hysteroscopic morcellation;   Procedure: Standard hysteroscopic resection
37 Recruiting A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)
Conditions: Malignant Solid Tumor;   Lymphoma, Large B-Cell, Diffuse;   Carcinoma, Non-Small-Cell Lung;   Transitional Cell Carcinoma of Urinary Tract;   Triple Negative Breast Cancer;   Carcinoma, Squamous Cell of Head and Neck;   Ovarian Neoplasms;   Adenocarcinoma of the Endometrium;   Renal Cell Carcinoma;   Microsatellite-instability (MSI) High Colorectal Cancer
Interventions: Drug: MK-3475;   Drug: INCB024360
38 Recruiting Suitability of DCE-MRI for Detection of Vascular Changes After VBT
Condition: Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Intervention: Radiation: Radiotherapy
39 Recruiting Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
Conditions: Recurrent Uterine Corpus Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Cancer;   Recurrent Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
40 Recruiting Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Conditions: Endometrial Atypical Hyperplasia;   Endometrial Adenocarcinoma
Interventions: Drug: Megestrol acetate and metformin;   Drug: Megestrol acetate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years